Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 455-459

  Hassan, Raffit ^a   Schweizer, Charles ^b   Lu, Kun F ^a   Schuler, Barbara ^a   Remaley, Alan T ^c   Weil, Susan C ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Morphotek Inc   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CA 125; Mesothelin; Mesothelioma; Metastasis; MORAb 009; Ovarian cancer; Peritoneal mesothelioma

Indexed keywords

CA 125 ANTIGEN; MESOTHELIN; MONOCLONAL ANTIBODY; MORAB 009; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MEMBRANE PROTEIN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MESOTHELIUM CELL; METASTASIS; MULTIPLE CYCLE TREATMENT; PERITONEAL CAVITY; PERITONEUM MESOTHELIOMA; PHASE 1 CLINICAL TRIAL; PLEURA CAVITY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; SERUM SICKNESS; SIDE EFFECT; BLOOD; CELL ADHESION; DISEASE COURSE; IMMUNOLOGY; IMMUNOTHERAPY; MESOTHELIOMA; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL; CA-125 ANTIGEN; CELL ADHESION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; GPI-LINKED PROTEINS;

EID: 77952551039     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.07.016     Document Type: Article

References (29)

1. Chang K., Pastan I., Willingham M.C. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992, 50:373-381.
2. Chang K., Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996, 93:136-140.
3. Ordóñez N.G. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003, 16:192-197.
4. Argani P., Iacobuzio-Donahue C., Ryu B., et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001, 7:3862-3868.
5. Hassan R., Laszik Z.G., Lerner M., Raffeld M., Postier R., Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005, 124:838-845.
6. Hassan R., Kreitman R.J., Pastan I., Willingham M.C. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005, 13:243-247.
7. Ordóñez N.G. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003, 27:1418-1428.
8. Yamaguchi N., Hattori K., Oh-eda M., Kojima T., Imai N., Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 1994, 269:805-808.
9. Hassan R., Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008, 44:46-53.
10. Robinson B.W., Creaney J., Lake R., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616.
11. Hassan R., Remaley A.T., Sampson M.L., et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006, 12:447-453.
12. Bera T.K., Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000, 20:2902-2906.
13. Prieve M.G., Moon R.T. Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. BMC Dev Biol 2003, 3:2.
14. Rump A., Morikawa Y., Tanaka M., et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004, 279:9190-9198.
15. Gubbels J.A.A., Belisle J., Onda M., et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006, 5:50-65.
16. Bast R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68:1331-1337.
17. Kabawat S.E., Bast R.C., Bhan A.K., Welch W.R., Knapp R.C., Colvin R.B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983, 2:275-285.
18. Fuith L.C., Daxenbichier G., Dapunt O. CA 125 in the serum and tissue of patients with gynecological disease. Arch Gynecol Obstet 1987, 241:157-164.
19. Kushitani K., Takeshima Y., Amatya V.J., Furonaka O., Sakatani A., Inai K. Immunohistochemical marker panels for distinguishing between epitheloid mesothelioma and lung adenocarcinoma. Pathol Int 2007, 57:190-199.
20. Bateman A.C., al-Talib R.K., Newman T., Williams J.H., Herbert A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 1997, 30:49-56.
21. Bast R.C., Badgwell D., Lu Z., et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005, 15(Suppl. 3):274-281.
22. Baratti D., Kusamura S., Martinetti A., et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthemic perfusion. Ann Surg Oncol 2007, 14:500-508.
23. Simsek H., Kadayifci A., Okan E. Importance of serum CA 125 levels in malignant peritoneal mesothelioma. Tumour Biol 1996, 17:1-4.
24. Yin B.W.T., Lloyd K.O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001, 276:27371-27375.
25. O'Brien T.J., Beard J.B., Underwood L.J., Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002, 23:154-169.
26. Hassan R., Ebel W., Routhier E.L., et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007, 7:20.
27. Chowdhury P.S., Viner J.L., Beers R., Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA 1998, 95:669-674.
28. Laheru D.A., Cohen S.J., Phillips D.K., et al. A phase I study of MORAb-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer. Presented at the 44th ASCO annual meeting, developmental therapeutics: molecular therapeutics session 2008, Abstract #3578.
29. Bertholf R.L., Johannsen L., Guy B. False elevation of serum CA-125 level caused by human anti-mouse antibodies. Ann Clin Lab Sci 2002, 32:414-418.